Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals is a global biopharmaceutical manufacturer that develops, produces, and distributes generic pharmaceuticals, specialty branded drugs, biosimilars, and injectable products. The company operates across multiple therapeutic areas, with particular focus on central nervous system disorders such as Parkinson's disease and endocrine conditions including hypothyroidism. Its specialty portfolio includes Rytary, a carbidopa-levodopa formulation for Parkinson's disease treatment, along with branded products targeting thyroid and neurological indications.

The company is organized into three operational segments. The Affordable Medicines segment manufactures a broad range of generic dosage forms and delivery systems, encompassing immediate and extended-release oral solids, sterile injectables, nasal sprays, inhalation products, biosimilars, ophthalmics, transdermal patches, and topical formulations. The Specialty segment focuses on branded pharmaceutical development and commercialization within its therapeutic niches. The AvKARE segment supplies pharmaceuticals and medical products primarily to government entities, the Department of Defense, and the Department of Veterans Affairs, while also serving retail and institutional customers through packaged pharmaceutical distribution.

Amneal operates with approximately 8,300 full-time employees and maintains headquarters in Bridgewater, New Jersey. The company distributes its products through wholesalers, retail pharmacies, hospitals, managed care organizations, government agencies, and other institutional channels, with operations spanning multiple geographic markets globally.